Other Stories

Samsung BioLogics suspended from stock market for accounting scandal Updated: 2018-11-14 16:24:12 KST

The biopharmaceutical arm of Samsung Group, Samsung BioLogics, has been found to have breached accounting standards and inflated its profits.
As a result, trading of the company's shares on Korea's benchmark KOSPI has been immediately suspended.
Also, the company will be subject to punitive examination for delisting.
South Korea's Securities and Futures Commission said Wednesday that it found the company had intentionally inflated its profits in 2015.
Meanwhile, Samsung BioLogics denied any wrongdoing saying it reflected different accounting standards in the event its unlisted joint venture Samsung Bioepis exercised its call option.
Samsung BioLogics is owned by tech giant Samsung Electronics and Samsung C&T, of which Samsung Electronics Vice Chairman and the Group's heir, Lee Jae-yong, is the biggest shareholder.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.
weather